Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC.

Pillai RN, Brodie SA, Sica GL, Shaojin Y, Li G, Nickleach DC, Yuan L, Varma VA, Bonta D, Herman JG, Brock MV, Ribeiro MJ, Ramalingam SS, Owonikoko TK, Khuri FR, Brandes JC.

Clin Cancer Res. 2013 Mar 15;19(6):1603-11. doi: 10.1158/1078-0432.CCR-12-2995. Epub 2013 Feb 5.

PMID:
23386692
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients.

Salazar F, Molina MA, Sanchez-Ronco M, Moran T, Ramirez JL, Sanchez JM, Stahel R, Garrido P, Cobo M, Isla D, Bertran-Alamillo J, Massuti B, Cardenal F, Manegold C, Lianes P, Trigo JM, Sanchez JJ, Taron M, Rosell R.

Lung Cancer. 2011 Apr;72(1):84-91. doi: 10.1016/j.lungcan.2010.07.008. Epub 2010 Aug 11.

PMID:
20705357
[PubMed - indexed for MEDLINE]
3.

Alternative efficacy-predicting markers for paclitaxel instead of CHFR in non-small-cell lung cancer.

Takeshita M, Koga T, Takayama K, Yano T, Maehara Y, Nakanishi Y, Sueishi K.

Cancer Biol Ther. 2010 Nov 1;10(9):933-41. doi: 10.4161/cbt.10.9.13320. Epub 2010 Nov 1.

PMID:
20855974
[PubMed - indexed for MEDLINE]
Free Article
4.

The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.

Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH.

Lung Cancer. 2010 Jun;68(3):478-83. doi: 10.1016/j.lungcan.2009.07.004. Epub 2009 Aug 15.

PMID:
19683826
[PubMed - indexed for MEDLINE]
5.

βV-tubulin expression is associated with outcome following taxane-based chemotherapy in non-small cell lung cancer.

Christoph DC, Kasper S, Gauler TC, Loesch C, Engelhard M, Theegarten D, Poettgen C, Hepp R, Peglow A, Loewendick H, Welter S, Stamatis G, Hirsch FR, Schuler M, Eberhardt WE, Wohlschlaeger J.

Br J Cancer. 2012 Aug 21;107(5):823-30. doi: 10.1038/bjc.2012.324. Epub 2012 Jul 26.

PMID:
22836512
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.

Kim SH, Lee GW, Lee MJ, Cho YJ, Jeong YY, Kim HC, Lee JD, Hwang YS, Kim IS, Lee S, Oh SY.

Lung Cancer. 2012 Sep;77(3):578-84. doi: 10.1016/j.lungcan.2012.04.016. Epub 2012 May 18.

PMID:
22608006
[PubMed - indexed for MEDLINE]
7.

Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.

Khambata-Ford S, Harbison CT, Hart LL, Awad M, Xu LA, Horak CE, Dakhil S, Hermann RC, Lynch TJ, Weber MR.

J Clin Oncol. 2010 Feb 20;28(6):918-27. doi: 10.1200/JCO.2009.25.2890. Epub 2010 Jan 25.

PMID:
20100958
[PubMed - indexed for MEDLINE]
8.

CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer.

Koga T, Takeshita M, Yano T, Maehara Y, Sueishi K.

Int J Cancer. 2011 Mar 1;128(5):1009-17. doi: 10.1002/ijc.25447.

PMID:
20473935
[PubMed - indexed for MEDLINE]
9.

A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.

Kosmas C, Tsavaris N, Syrigos K, Koutras A, Tsakonas G, Makatsoris T, Mylonakis N, Karabelis A, Stathopoulos GP, Kalofonos HP.

Cancer Chemother Pharmacol. 2007 Jan;59(1):51-9. Epub 2006 Apr 19.

PMID:
16622691
[PubMed - indexed for MEDLINE]
10.

RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.

Zhang GB, Chen J, Wang LR, Li J, Li MW, Xu N, Wang Y, Shentu JZ.

Cancer Chemother Pharmacol. 2012 May;69(5):1277-87. doi: 10.1007/s00280-012-1834-x.

PMID:
22302408
[PubMed - indexed for MEDLINE]
11.

[Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].

Shi Y, Chen L, Li J, Lü YL, Jiao SC.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2010 Aug;32(4):375-82. doi: 10.3881/j.issn.1000-503X.2010.04.004. Chinese.

PMID:
20868593
[PubMed - indexed for MEDLINE]
Free Article
12.

Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.

Hirsch FR, Herbst RS, Olsen C, Chansky K, Crowley J, Kelly K, Franklin WA, Bunn PA Jr, Varella-Garcia M, Gandara DR.

J Clin Oncol. 2008 Jul 10;26(20):3351-7. doi: 10.1200/JCO.2007.14.0111.

PMID:
18612151
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.

Yan D, Wei P, An G, Chen W.

J Cardiothorac Surg. 2013 Jun 10;8:149. doi: 10.1186/1749-8090-8-149.

PMID:
23759026
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.

Ramirez JL, Rosell R, Taron M, Sanchez-Ronco M, Alberola V, de Las Peñas R, Sanchez JM, Moran T, Camps C, Massuti B, Sanchez JJ, Salazar F, Catot S; Spanish Lung Cancer Group.

J Clin Oncol. 2005 Dec 20;23(36):9105-12.

PMID:
16361617
[PubMed - indexed for MEDLINE]
15.

Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.

Banno K, Yanokura M, Kawaguchi M, Kuwabara Y, Akiyoshi J, Kobayashi Y, Iwata T, Hirasawa A, Fujii T, Susumu N, Tsukazaki K, Aoki D.

Int J Oncol. 2007 Oct;31(4):713-20.

PMID:
17786301
[PubMed - indexed for MEDLINE]
16.

Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.

Hwang JE, Hong JY, Kim K, Kim SH, Choi WY, Kim MJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Lee KH, Lee JH, Cho SH, Chung IJ.

BMC Cancer. 2013 Sep 23;13:431. doi: 10.1186/1471-2407-13-431.

PMID:
24053422
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.

de Fraipont F, Levallet G, Creveuil C, Bergot E, Beau-Faller M, Mounawar M, Richard N, Antoine M, Rouquette I, Favrot MC, Debieuvre D, Braun D, Westeel V, Quoix E, Brambilla E, Hainaut P, Moro-Sibilot D, Morin F, Milleron B, Zalcman G; Intergroupe Francophone de Cancérologie Thoracique.

Clin Cancer Res. 2012 May 15;18(10):2976-86. doi: 10.1158/1078-0432.CCR-11-2797. Epub 2012 Mar 20.

PMID:
22434665
[PubMed - indexed for MEDLINE]
Free Article
18.

The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy.

Kaira K, Takahashi T, Murakami H, Shukuya T, Kenmotsu H, Ono A, Naito T, Tsuya A, Nakamura Y, Endo M, Kondo H, Nakajima T, Yamamoto N.

Int J Clin Oncol. 2013 Jun;18(3):371-9. doi: 10.1007/s10147-012-0386-8. Epub 2012 Feb 23.

PMID:
22358390
[PubMed - indexed for MEDLINE]
19.

DNA methylation of CHFR is not a predictor of the response to docetaxel and paclitaxel in advanced and recurrent gastric cancer.

Yoshida K, Hamai Y, Suzuki T, Sanada Y, Oue N, Yasui W.

Anticancer Res. 2006 Jan-Feb;26(1A):49-54.

PMID:
16475678
[PubMed - indexed for MEDLINE]
Free Article
20.

The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.

Nakata S, Sugio K, Uramoto H, Oyama T, Hanagiri T, Morita M, Yasumoto K.

Cancer. 2006 May 15;106(10):2190-9.

PMID:
16598757
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk